Quarterly report pursuant to Section 13 or 15(d)

Note 1 - Corporate Information (Details Textual)

v3.23.2
Note 1 - Corporate Information (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Sep. 30, 2023
Jul. 18, 2023
Dec. 31, 2022
May 31, 2013
Cash, Cash Equivalents, and Short-Term Investments $ 54,900   $ 54,900          
Net Income (Loss) Attributable to Parent 3,976 $ (10,338) (9,207) $ (15,439)        
Retained Earnings (Accumulated Deficit) $ (299,628)   $ (299,628)       $ (290,421)  
Forecast [Member]                
Reduction in Workforce, Cost         $ 3,400      
Subsequent Event [Member]                
Reduction in Workforce, Percentage           70.00%    
Pieris Pharmaceuticals GmbH [Member]                
Business Acquisition, Percentage of Voting Interests Acquired               100.00%